Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade

Tempus AI's Chief Legal Officer Andrew Polovin sold 30,075 shares worth $1.5 million in a non-discretionary transaction to cover tax withholding obligations from RSU vesting. The sale occurred during a 75% stock rally driven by positive results from a Moderna-Merck cancer vaccine trial validating Tempus's genomic sequencing technology. The company reported 22% revenue growth to $382.5 million last quarter and achieved its first GAAP profit, though it remains unprofitable on a TTM basis with -$254.4 million net income.